 PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. BridgeBio Nasdaq: BBIO and Eidos Therapeutics, Inc. Eidos Nasdaq: EIDX announced today that the acquisition of shares of common stock of Eidos not held by BridgeBio or its subsidiaries, on the terms and subject to the conditions of their previously announced merger agreement, is expected to close on or about January 26, 2021. The closing of the transaction is subject to the receipt of approvals from BridgeBio and Eidos stockholders at special meetings of each companys stockholders, both of which are scheduled for January 19, 2021, and the satisfaction or waiver of other conditions to closing. Leading proxy advisory firms Institutional Shareholder Services and Glass Lewis recommend that BridgeBio and Eidos stockholders vote FOR BridgeBios proposed merger with Eidos and each of the other proposals to be considered at both companies virtual special meetings. 